Volume 1:

Volume 2:

Volume 3:

Advances in genomics, combinatorial chemistry, assay development and automated high throughput screening technologies coupled with the development of computational models have created enormous opportunities in pharmaceutical research. Selection of lead compounds is no longer just based on favorable target interaction, but increasingly incorporates early compound screening for other parameters critical to clinical success later on in development.

Using a combination of computational and experimental methods, models to predict clinical performance of compounds are now developed and used as early as the screening stage to optimize lead selection from combinatorial libraries.

High throughput in vitro assays measuring drug metabolism, toxicity, drug-drug interactions, oral absorption, and blood brain barrier permeability give advance information on a compound's risk profile long before it is tested in animals or humans.

Databases correlating molecular structure to these pharmacological properties enable the industry to design molecules to be more drug-like from the outset.

In this report, industry experts provide practical insights into how and when to optimize lead selection to minimize risk during later stages of development. The report is divided into three volumes, each focusing on one of the major approaches taken by the industry to reduce risk:

• construction of physiologically relevant high throughput screening assays to evaluate toxicity and efficacy of compounds early on (volume I);
  
• development of integrated databases and computer-based models to better predict clinical performance of a compound during discovery (volume II);
  
• decision strategies and predictive models for early go/no-go decisions during discovery and development (volume III).

Each volume is available separately or in combination with any of the other volumes. The report and its volumes are available as printed hardcopies and searchable CD-ROMs.

Report Features:

• fully edited transcripts with commentaries, exhibits and weblinks
  
• available as searchable CD-ROM and printed hardcopy; multi-copy licenses available

Publication Date: November, 1999

Who Should Read This Report?
Pharmaceutical or Biotechnology Company Executives working in Project Management, Program Management, Knowledge Management, R&D, Discovery, Drug Metabolism, Toxicology, Pharmacology, Preclinical or Clinical Operations.

Pricing:
All 3 Volumes - $2,490
Volume 1 - High Throughput Screening Assay - $1,290
Volume 2 - In Silico Biology - $1,290
Volume 3 - Early Compound Attrition - $1,290